ReviewsPandemic Autopsy Biosafety ConsiderationsBrooks, Erin G. MDAuthor Information From the Department of Pathology & Laboratory Medicine, University of Wisconsin Hospital and Clinics, Madison, WI. Reprints: Erin G. Brooks, MD, Department of Pathology & Laboratory Medicine, University of Wisconsin Hospital and Clinics, 600 Highland Ave, L5/149 CSC, Madison, WI 53792. E-mail: [email protected]. The author has no funding or conflicts to declare. AJSP: Reviews & Reports: 3/4 2021 - Volume 26 - Issue 2 - p 93-99 doi: 10.1097/PCR.0000000000000434 Buy Metrics Abstract At autopsy, prosectors have always risked exposure to a wide array of infectious agents. With the recent advent of the SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) pandemic, such exposure concerns have increased dramatically. Careful assessment of facility infrastructure and appropriate biosafety training, however, can minimize risks and allow for safe autopsy performance. As with other disease outbreaks, the living have much to learn from the dead. To date, autopsy studies have been critical in elucidating the mechanisms by which COVID-19 (coronavirus disease 2019) may critically compromise not only pulmonary but also cerebral, cardiac, and renal function. Much remains unknown, though, and further tissue-based research is called for. The following review is intended to detail best practices and principles for autopsy biosafety, with a focus on issues specific to the current pandemic. Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.